Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL004
MIFTS: 55

Oral Submucous Fibrosis

Categories: Rare diseases, Gastrointestinal diseases, Oral diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Oral Submucous Fibrosis

About this section

MalaCards integrated aliases for Oral Submucous Fibrosis:

Name: Oral Submucous Fibrosis 12 76 53 59 55 44 15 73
Oral Submucosal Fibrosis, Including of Tongue 12 73
Osmf 53 59
Oral Cavity Submucous Fibrosis 12
Oral Submucosal Fibrosis 12

Characteristics:

Orphanet epidemiological data:

59
oral submucous fibrosis
Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 33 34


External Ids:

Disease Ontology 12 DOID:5773
ICD10 33 K13.5
ICD9CM 35 528.8
MeSH 44 D009914
NCIt 50 C34866
SNOMED-CT 68 32883009
Orphanet 59 ORPHA357154
ICD10 via Orphanet 34 K13.5
UMLS via Orphanet 74 C0029172
Sources

Summaries for Oral Submucous Fibrosis

About this section
NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 357154Disease definitionOral submucous fibrosis (OSMF) is a chronic, progressive disease that alters the fibroelasticity of the oral submucosa, prevalent in India and Southeast Asia but rare elsewhere, and characterized by burning and pain in the oral cavity, loss of gustatory sensation, the presence of blanched fibrous bands and stiffening of the oral mucosa and oro-pharynx (leading to trismus and a progressive reduction in mouth opening) and an increased risk of developing oral squamous cellcancer (3-19%). It is usually associated with the chewing of the areca nut (an ingredient in betel quid) but the exact etiology is unknown and there is currently no effective treatment.Visit the Orphanet disease page for more resources.

MalaCards based summary : Oral Submucous Fibrosis, also known as oral submucosal fibrosis, including of tongue, is related to leukoplakia and oral cancer, and has symptoms including oral manifestations An important gene associated with Oral Submucous Fibrosis is LOX (Lysyl Oxidase), and among its related pathways/superpathways are Drug metabolism - cytochrome P450 and Gastric cancer. The drugs Hyaluronic acid and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include tongue, skin and endothelial, and related phenotypes are narrow mouth and trismus

Wikipedia : 76 Oral submucous fibrosis (OSMF or OSF) is a chronic, complex, premalignant (1% transformation risk)... more...

Sources

Related Diseases for Oral Submucous Fibrosis

About this section

Diseases related to Oral Submucous Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 leukoplakia 31.2 CYP1A1 GSTM1 GSTT1
2 oral cancer 28.8 CDH1 CYP1A1 GSTM1 GSTT1 MMP2 PTGS2
3 leukoregulin 10.7 PTGS2 TGFB1
4 hearing loss, noise-induced 10.6 GSTM1 GSTT1
5 diabetic foot ulcers 10.6 TGFB1 TIMP1
6 sister chromatid exchange, frequency of 10.6 GSTM1 GSTT1
7 squamous cell carcinoma 10.6
8 isolated cleft lip 10.6 GSTM1 GSTT1
9 oral squamous cell carcinoma 10.5
10 drug-induced hepatitis 10.5 GSTM1 GSTT1
11 fibromatosis, gingival, 1 10.5 MMP2 TGFB1
12 mucositis 10.4
13 toxic oil syndrome 10.4 CYP1A1 GSTM1
14 oral leukoplakia 10.4
15 adenomyosis 10.4 MMP2 PTGS2
16 conjunctival nevus 10.3 MMP2 TIMP1
17 conjunctivochalasis 10.3 MMP2 TIMP1
18 nasal cavity squamous cell carcinoma 10.3 MMP2 TIMP1
19 clopidogrel resistance 10.2 CYP1A1 PTGS2
20 osteoarthritis 10.2 PTGS2 TGFB1 TIMP1
21 vulvar intraepithelial neoplasia 10.2 CDH1 MMP2
22 sorsby fundus dystrophy 10.2 MMP2 TIMP1
23 pulmonary disease, chronic obstructive 10.2 GSTM1 TGFB1 TIMP1
24 urinary tract obstruction 10.1 CDH1 PTGS2 TGFB1
25 hypertrophic scars 10.1 MMP2 TGFB1 TIMP1
26 gingival fibromatosis 10.1 MMP2 TGFB1 TIMP1
27 norwegian scabies 10.1 GSTM1 TGFB1
28 aging 10.1
29 burns 10.1
30 pemphigus 10.1
31 larynx cancer 10.1 GSTM1 GSTT1 MMP2
32 diffuse gastric cancer 10.0 CDH1 GSTM1 GSTT1
33 keratoconus 10.0 LOX MMP2 TIMP1
34 pemphigus vulgaris, familial 10.0
35 pemphigus vulgaris 10.0
36 papilloma 10.0
37 gingivitis 10.0
38 burning mouth syndrome 10.0
39 oral lichen planus 10.0
40 gastrointestinal system cancer 9.9 CDH1 MMP2 PTGS2
41 microcystic meningioma 9.8 CDH1 MMP2 TIMP1
42 masticatory muscles, hypertrophy of 9.8
43 myositis 9.8
44 body mass index quantitative trait locus 1 9.8
45 anxiety 9.8
46 muscle hypertrophy 9.8
47 deficiency anemia 9.8
48 diabetes mellitus 9.8
49 disseminated intravascular coagulation 9.8
50 iron deficiency anemia 9.8

Graphical network of the top 20 diseases related to Oral Submucous Fibrosis:



Diseases related to Oral Submucous Fibrosis
Sources

Symptoms & Phenotypes for Oral Submucous Fibrosis

About this section

Human phenotypes related to Oral Submucous Fibrosis:

59 32 (show all 7)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 narrow mouth 59 32 hallmark (90%) Very frequent (99-80%) HP:0000160
2 trismus 59 32 frequent (33%) Frequent (79-30%) HP:0000211
3 abnormality of the pharynx 59 32 hallmark (90%) Very frequent (99-80%) HP:0000600
4 flexion contracture 59 32 frequent (33%) Frequent (79-30%) HP:0001371
5 oropharyngeal squamous cell carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0012182
6 cheilitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100825
7 abnormality of the oral cavity 59 Very frequent (99-80%)

UMLS symptoms related to Oral Submucous Fibrosis:


oral manifestations

GenomeRNAi Phenotypes related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CDH1 DKK3 FLNA GSTM1 MMP2 PTGS2

MGI Mouse Phenotypes related to Oral Submucous Fibrosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 PTGS2 CDH1 SFRP4 CYP1A1 TGFB1 FLNA
2 homeostasis/metabolism MP:0005376 9.96 PTGS2 CDH1 SFRP4 CYP1A1 DKK3 TGFB1
3 hematopoietic system MP:0005397 9.92 PTGS2 SFRP4 CYP1A1 DKK3 TGFB1 FLNA
4 immune system MP:0005387 9.81 PTGS2 CDH1 SFRP4 CYP1A1 DKK3 TGFB1
5 neoplasm MP:0002006 9.35 MMP2 PTGS2 CDH1 TGFB1 TIMP1
6 respiratory system MP:0005388 9.17 PTGS2 SFRP4 TGFB1 FLNA TIMP1 LOX
Sources

Drugs & Therapeutics for Oral Submucous Fibrosis

About this section

Drugs for Oral Submucous Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
2
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
3
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
4 Anti-Inflammatory Agents Phase 3,Phase 2
5 Adjuvants, Immunologic Phase 3
6 Cortisol succinate Phase 3
7 Hydrocortisone 17-butyrate 21-propionate Phase 3
8 Hydrocortisone acetate Phase 3
9 Viscosupplements Phase 3
10 Hydrocortisone-17-butyrate Phase 3
11 Antioxidants Phase 3
12 Protective Agents Phase 3
13
Curcumin Approved, Investigational Phase 2 458-37-7 969516
14
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
15
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
16
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
17 tannic acid Approved, Nutraceutical Phase 2
18
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
19 Analgesics Phase 2
20 Analgesics, Non-Narcotic Phase 2
21 Peripheral Nervous System Agents Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 2
23 Antirheumatic Agents Phase 2
24 Antimetabolites Phase 2
25 Antimetabolites, Antineoplastic Phase 2
26 Astragalus Nutraceutical Phase 2
27 Antibodies
28 Immunoglobulins
29 Autoantibodies

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study Completed NCT02714543 Phase 3 aloevera juice;Hydrocortisone;Hyaluronic Acid;antioxidant;aloevera gel
2 Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF) Unknown status NCT02645656 Phase 2 Curcumin Arm
3 Efficacy of Curcumin in Oral Submucous Fibrosis Recruiting NCT03511261 Phase 2 10% Curcumin mucoadhesive gel;Curcumin capsules 500mg;5% curcumin mucoadhesive gel + Curcumin capsules 250 mg;Placebo capsule
4 A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy Terminated NCT01720563 Phase 2 Astragalus polysaccharides 500 mg;Placebo
5 Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis Completed NCT03011086
6 Use of Single Staged Nasolabial Flap in Oral Submucous Fibrosis Completed NCT02711046 Not Applicable

Search NIH Clinical Center for Oral Submucous Fibrosis

Cochrane evidence based reviews: oral submucous fibrosis

Sources

Genetic Tests for Oral Submucous Fibrosis

About this section
Sources

Anatomical Context for Oral Submucous Fibrosis

About this section

MalaCards organs/tissues related to Oral Submucous Fibrosis:

41
Tongue, Skin, Endothelial, T Cells, Testes, Salivary Gland, Liver
Sources

Publications for Oral Submucous Fibrosis

About this section

Articles related to Oral Submucous Fibrosis:

(show top 50) (show all 569)
# Title Authors Year
1
Endorsing cellular competitiveness in aberrant epithelium of oral submucous fibrosis progression: neighbourhood analysis of immunohistochemical attributes. ( 29687243 )
2018
2
Angiogenesis and Fibrogenesis in Oral Submucous Fibrosis: A Viewpoint. ( 29422478 )
2018
3
Bibliometric analysis of 100 most cited articles on oral submucous fibrosis. ( 29905986 )
2018
4
Conservative management of Oral Submucous Fibrosis in early and intermediate stage. ( 29892527 )
2018
5
Butylidenephthalide abrogates the myofibroblasts activation and mesenchymal transdifferentiation in oral submucous fibrosis. ( 29665273 )
2018
6
miR-200b ameliorates myofibroblast transdifferentiation in precancerous oral submucous fibrosis through targeting ZEB2. ( 29893466 )
2018
7
Hinokitiol ablates myofibroblast activation in precancerous oral submucous fibrosis by targeting Snail. ( 29328529 )
2018
8
"A Comparative Clinical Evaluation of the Buccal Fat Pad and Extended Nasolabial Flap in the Reconstruction of the Surgical Defect in Oral Submucous Fibrosis Patients": A Commentary. ( 29859162 )
2018
9
Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry ( 29699065 )
2018
10
Comment on "TFM classification and staging of oral submucous fibrosis: A new proposal". ( 29682779 )
2018
11
Data regarding clinical evaluation of collagen membrane in oral mucosal defects due to oral submucous fibrosis and leukoplakia. ( 29900214 )
2018
12
New research directions for areca nut/betel quid and oral submucous fibrosis for holistic prevention and treatment. ( 29428570 )
2018
13
Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis. ( 29652009 )
2018
14
Reply to: Comment on "TFM classification and staging of oral submucous fibrosis: A new proposal". ( 29719926 )
2018
15
A comparative study to evaluate the efficacy of lycopene and curcumin in oral submucous fibrosis patients: A randomized clinical trial. ( 29900913 )
2018
16
Serum-based diagnostic prediction of oral submucous fibrosis using FTIR spectrometry. ( 28826108 )
2018
17
Oral submucous fibrosis: A clinico-histopathological correlational study. ( 29893325 )
2018
18
Validity of Chronic Oral Mucosal Diseases Questionnaire in oral submucous fibrosis. ( 29948274 )
2018
19
Expression of I^1integrin in normal epithelium, oral submucous fibrosis and oral squamous cell carcinoma. ( 29113685 )
2018
20
Impact of oral submucous fibrosis on oral health-related quality of life: A condition-specific OHRQoL-OSF instrument analysis. ( 29928774 )
2018
21
Significance of Serum Nitric Oxide and Superoxide Dismutase in Oral Submucous Fibrosis and Squamous Cell Carcinoma: A Comparative Study. ( 29875574 )
2018
22
Assessment of the quality of life and performance status in patients with oral submucous fibrosis in central India. ( 29785159 )
2018
23
TFM classification and Staging of oral submucous fibrosis: A new proposal. ( 29405430 )
2018
24
Fibrotomy with diode laser (980A nm) and habit correlation in oral submucous fibrosis: a report of 30 cases. ( 29948450 )
2018
25
Mouth-opening device as a treatment modality in trismus patients with head and neck cancer and oral submucous fibrosis: a prospective study. ( 29696422 )
2018
26
Is matrix stiffness a cause for malignant transformation of oral submucous fibrosis? ( 29656454 )
2018
27
Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis - An Ultrasonographic Study. ( 28839403 )
2017
28
Oral submucous fibrosis: An update. ( 29391702 )
2017
29
Prosthetic rehabilitation of oral submucous fibrosis patients: A systematic review of published case reports and case series. ( 28877246 )
2017
30
Early Stage Oral Submucous Fibrosis is Characterized by Increased Vascularity as Opposed to Advanced Stages. ( 28658917 )
2017
31
An update on studies on etiological factors, disease progression, and malignant transformation in oral submucous fibrosis. ( 28862199 )
2017
32
Oral submucous fibrosis: Newer proposed classification with critical updates in pathogenesis and management strategies. ( 29386809 )
2017
33
Oral submucous fibrosis in a school-going Indian adolescent boy. ( 28731854 )
2017
34
Comparison of Extended Nasolabial Flap Versus Buccal Fat Pad Graft in the Surgical Management of Oral Submucous Fibrosis: A Prospective Pilot Study. ( 28717289 )
2017
35
Micronucleus Assay: An Early Diagnostic Tool to Assess Genotoxic Changes in Patients with Tobacco Use, Oral Leukoplakia and Oral Submucous Fibrosis. ( 29207828 )
2017
36
LncRNA GAS5-AS1 inhibits myofibroblasts activities in oral submucous fibrosis. ( 29249416 )
2017
37
Correlation of ultrasonographic measurements, histopathological grading, and clinical staging in oral submucous fibrosis. ( 29072206 )
2017
38
A Comparative Clinical Evaluation of the Buccal Fat Pad and Extended Nasolabial Flap in the Reconstruction of the Surgical Defect in Oral Submucous Fibrosis Patients. ( 29223311 )
2017
39
Oral submucous fibrosis: A quantitative assessment of serum malondialdehyde, superoxide dismutase and correlation with clinical staging. ( 28479685 )
2017
40
Evaluation of myofibroblasts in oral submucous fibrosis and oral squamous cell carcinoma: The pathogenesis and correlation. ( 29109745 )
2017
41
Developing a quality-of-life questionnaire for oral submucous fibrosis patients. ( 28865104 )
2017
42
PTMA, a new identified autoantigen for oral submucous fibrosis, regulates oral submucous fibroblast proliferation and extracellular matrix. ( 29088825 )
2017
43
Identification of over expressed proteins in Oral Submucous Fibrosis by proteomic analysis. ( 28980718 )
2017
44
Evaluation of role of trace elements in oral submucous fibrosis patients: A study on Gujarati population. ( 29391727 )
2017
45
Total Serum Protein Estimation and Its Correlation with Clinical and Histopathological Grading using Masson's Trichrome Stain in Patients of Oral Submucous Fibrosis. ( 28839417 )
2017
46
Effectiveness of Osteopathic Therapy in the Treatment of Oral Submucous Fibrosis. ( 28566867 )
2017
47
Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis. ( 28761276 )
2017
48
Comparative Evaluation of Serum Lipid Profile in Patients with Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma with that of Control Subjects: A Case Control Study. ( 29284962 )
2017
49
Cyclophilin A was revealed as a candidate marker for human oral submucous fibrosis by proteomic analysis. ( 28826174 )
2017
50
Oral submucous fibrosis-an increasing global healthcare problem. ( 28672092 )
2017
Sources

Variations for Oral Submucous Fibrosis

About this section
Sources

Expression for Oral Submucous Fibrosis

About this section
Search GEO for disease gene expression data for Oral Submucous Fibrosis.
Sources

Pathways for Oral Submucous Fibrosis

About this section

Pathways related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Drug metabolism - cytochrome P450 37
Show member pathways
 12.53 CYP1A1 GSTM1 GSTT1 PTGS2
2
Gastric cancer 37
Show member pathways
 12.49 CDH1 GSTM1 GSTT1 TGFB1
3
Degradation of the extracellular matrix 66
Show member pathways
 12.42 CDH1 LOX MMP2 TGFB1 TIMP1
4
Pathways in cancer 37
12.15 CDH1 GSTM1 GSTT1 MMP2 PTGS2 TGFB1
5
Proteoglycans in cancer 37
12.06 FLNA MMP2 TGFB1
6
Colorectal Cancer Metastasis 64
11.84 CDH1 MMP2 PTGS2 TGFB1
7
Fluid shear stress and atherosclerosis 37
11.83 GSTM1 GSTT1 MMP2
8
SMAD Signaling Network 64
11.81 FLNA MMP2 TGFB1
9
Interleukin-4 and 13 signaling 66
11.61 MMP2 PTGS2 TGFB1 TIMP1
10
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics 61
Show member pathways
 11.51 CYP1A1 GSTM1 GSTT1
11
Lung fibrosis 1
11.38 MMP2 TGFB1 TIMP1
12
Syndecan-2-mediated signaling events 1
11.09 MMP2 TGFB1
13
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 61
11.02 GSTM1 GSTT1
14
Angiogenesis (CST) 4
10.87 MMP2 PTGS2 TGFB1 TIMP1
15
Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds 1
10.75 DKK3 SFRP4
16
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition 1
10.73 CDH1 TGFB1
17
Naphthalene metabolism 22
10.71 CYP1A1 GSTM1 GSTT1
18
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 61
10.63 GSTT1 PTGS2
Sources

GO Terms for Oral Submucous Fibrosis

About this section

Cellular components related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.17 CDH1 FLNA LOX MMP2 SFRP4 TGFB1

Biological processes related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.75 CYP1A1 MMP2 TGFB1
2 cytokine-mediated signaling pathway GO:0019221 9.73 MMP2 PTGS2 TGFB1 TIMP1
3 response to organic cyclic compound GO:0014070 9.7 CYP1A1 PTGS2 TGFB1
4 platelet degranulation GO:0002576 9.67 FLNA TGFB1 TIMP1
5 face morphogenesis GO:0060325 9.59 MMP2 TGFB1
6 positive regulation of vascular endothelial growth factor production GO:0010575 9.58 PTGS2 TGFB1
7 wound healing GO:0042060 9.58 LOX TGFB1 TIMP1
8 response to immobilization stress GO:0035902 9.57 CYP1A1 TGFB1
9 glutathione derivative biosynthetic process GO:1901687 9.56 GSTM1 GSTT1
10 aging GO:0007568 9.56 CYP1A1 PTGS2 TGFB1 TIMP1
11 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.55 DKK3 TGFB1
12 response to vitamin D GO:0033280 9.54 PTGS2 TGFB1
13 extracellular matrix disassembly GO:0022617 9.54 CDH1 MMP2 TIMP1
14 cell activation GO:0001775 9.51 TGFB1 TIMP1
15 response to hormone GO:0009725 9.5 LOX SFRP4 TIMP1
16 obsolete positive regulation of transcription factor import into nucleus GO:0042993 9.48 CDH1 FLNA
17 negative regulation of cell-cell adhesion GO:0022408 9.46 CDH1 TGFB1
18 response to drug GO:0042493 9.35 CDH1 CYP1A1 LOX PTGS2 TGFB1
19 positive regulation of protein import into nucleus GO:0042307 9.33 CDH1 PTGS2 TGFB1
20 response to organic substance GO:0010033 9.02 CDH1 CYP1A1 PTGS2 TGFB1 TIMP1

Molecular functions related to Oral Submucous Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.35 CDH1 FLNA GSTM1 PTGS2 TGFB1
2 enzyme binding GO:0019899 8.92 CYP1A1 GSTM1 PTGS2 TGFB1
Sources

Sources for Oral Submucous Fibrosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....